{"nctId":"NCT00389207","briefTitle":"Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults","startDateStruct":{"date":"2006-10"},"conditions":["HIV Infections"],"count":576,"armGroups":[{"label":"NVP bid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: nevirapine bid"]},{"label":"NVP qd","type":"EXPERIMENTAL","interventionNames":["Drug: nevirapine qd"]},{"label":"ATZ/r","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: atazanavir"]}],"interventions":[{"name":"nevirapine bid","otherNames":[]},{"name":"nevirapine qd","otherNames":[]},{"name":"atazanavir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nInclusion Criteria:\n\n1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation\n2. HIV-1-infected males or females \\>= 18 years of age with positive serology confirmed by Western blot\n3. No previous antiretroviral treatment (of more than 7 days)\n4. Males with CD4+ counts of \\< 400 cells/mm3 and females with CD4+ counts of \\< 250 cells/mm3\n5. NVP- and ATZ/r susceptibility based on HIV-1 genotypic resistance report\n6. Adequate renal function defined as a calculated creatinine clearance (CLCr) \\>= 50 ml/min according to the Cockcroft-Gault formula\n7. Karnofsky score \\>= 70\n8. Acceptable medical history, as assessed by the investigator\n\nExclusion criteria:\n\nExclusion Criteria:\n\n1. Active drug abuse or chronic alcoholism at the investigator's discretion\n2. Hepatic cirrhosis stage Child-Pugh B or C\n3. Female patients of child-bearing potential who:\n\n   * have a positive serum pregnancy test at screening or during the study,\n   * are breast feeding,\n   * are planning to become pregnant,\n   * are not willing to use a barrier method of contraception, or are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives\n4. Laboratory parameters Division of Acquired Immunodeficiency Syndrome (DAIDS) \\> grade 2 (triglycerides \\> DAIDS grade 3; total cholesterol no restrictions)\n5. Active hepatitis B or C disease, defined as HBsAg-positive or Hepatitis C-Virus-Ribo Nucleic Acid (HCV-RNA)- positive with Aspartate Transaminase/Alanine Transaminase (AST/ALT) \\> 2.5x Upper Limit of Normal (ULN) (DAIDS grade 1)\n6. Hypersensitivity to any ingredients of the test products\n7. Have therapy with nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, tacrolimus, cyclosporine) or potential competitors of renal excretion (e.g., cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir, probenecid, high-dose non-steroidal anti-inflammatory drugs (i.e., ibuprofen)) within 3 months prior to study screening or are expected to receive these during the study\n8. Patients who are receiving other concomitant treatments which are not permitted\n9. Use of other investigational medications within 30 days before study entry or during the trial\n10. Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2, chronic treatment with prednisone)\n11. Patients with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any lymphoma\n12. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit\n13. Patients who are receiving systemic treatment for malignant disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Response at Week 48","description":"Treatment response is defined as a viral load (VL) \\<50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"124","spread":null},{"groupId":"OG002","value":"250","spread":null},{"groupId":"OG003","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"126","spread":null},{"groupId":"OG003","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 48 (TLOVR Algorithm)","description":"Treatment response is defined as a VL \\<50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"261","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With VL < 50 Copies/ml","description":"VL \\<50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.107","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.304","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.515","spread":null},{"groupId":"OG001","value":"0.412","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.842","spread":null},{"groupId":"OG001","value":"0.779","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.907","spread":null},{"groupId":"OG001","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.931","spread":null},{"groupId":"OG001","value":"0.886","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.959","spread":null},{"groupId":"OG001","value":"0.901","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.965","spread":null},{"groupId":"OG001","value":"0.915","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.972","spread":null},{"groupId":"OG001","value":"0.896","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":null},{"groupId":"OG001","value":"0.924","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.964","spread":null},{"groupId":"OG001","value":"0.968","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.976","spread":null},{"groupId":"OG001","value":"0.955","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.971","spread":null},{"groupId":"OG001","value":"0.947","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.952","spread":null},{"groupId":"OG001","value":"0.929","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With VL < 400 Copies/ml","description":"VL \\<400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.365","spread":null},{"groupId":"OG001","value":"0.287","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.714","spread":null},{"groupId":"OG001","value":"0.679","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.856","spread":null},{"groupId":"OG001","value":"0.834","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.924","spread":null},{"groupId":"OG001","value":"0.956","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.968","spread":null},{"groupId":"OG001","value":"0.966","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.985","spread":null},{"groupId":"OG001","value":"0.977","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.993","spread":null},{"groupId":"OG001","value":"0.988","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.996","spread":null},{"groupId":"OG001","value":"0.988","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.988","spread":null},{"groupId":"OG001","value":"0.994","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.000","spread":null},{"groupId":"OG001","value":"0.987","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.996","spread":null},{"groupId":"OG001","value":"1.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.000","spread":null},{"groupId":"OG001","value":"0.994","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.996","spread":null},{"groupId":"OG001","value":"0.993","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.991","spread":null},{"groupId":"OG001","value":"0.986","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in CD4+ Count From Baseline","description":"Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":"93.5"},{"groupId":"OG001","value":"86.1","spread":"94.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105.6","spread":"108.0"},{"groupId":"OG001","value":"98.0","spread":"91.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.3","spread":"113.9"},{"groupId":"OG001","value":"110.9","spread":"111.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134.4","spread":"114.9"},{"groupId":"OG001","value":"133.8","spread":"110.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160.1","spread":"123.0"},{"groupId":"OG001","value":"163.4","spread":"119.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168.2","spread":"127.0"},{"groupId":"OG001","value":"183.6","spread":"121.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184.8","spread":"129.6"},{"groupId":"OG001","value":"208.2","spread":"144.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213.7","spread":"165.7"},{"groupId":"OG001","value":"231.9","spread":"165.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"223.0","spread":"147.1"},{"groupId":"OG001","value":"246.4","spread":"149.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217.7","spread":"133.5"},{"groupId":"OG001","value":"251.6","spread":"149.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231.2","spread":"148.9"},{"groupId":"OG001","value":"267.2","spread":"161.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231.3","spread":"147.6"},{"groupId":"OG001","value":"269.2","spread":"169.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243.4","spread":"164.8"},{"groupId":"OG001","value":"281.3","spread":"147.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"251.0","spread":"151.6"},{"groupId":"OG001","value":"285.8","spread":"164.8"}]}]}]},{"type":"SECONDARY","title":"Change in Framingham Score From Baseline","description":"Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"2.79"},{"groupId":"OG001","value":"0.66","spread":"2.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"3.15"},{"groupId":"OG001","value":"1.19","spread":"3.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"3.40"},{"groupId":"OG001","value":"0.82","spread":"3.03"}]}]}]},{"type":"SECONDARY","title":"Change in Mental Health Summary (MHS) Score From Baseline","description":"Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.09","spread":"9.31"},{"groupId":"OG001","value":"4.52","spread":"7.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.10","spread":"9.75"},{"groupId":"OG001","value":"4.89","spread":"9.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":"10.33"},{"groupId":"OG001","value":"4.70","spread":"10.14"}]}]}]},{"type":"SECONDARY","title":"Change in Physical Health Summary (PHS) Score From Baseline","description":"QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.34","spread":"7.77"},{"groupId":"OG001","value":"3.35","spread":"8.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":"7.83"},{"groupId":"OG001","value":"3.00","spread":"7.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":"8.77"},{"groupId":"OG001","value":"3.35","spread":"8.42"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Hospitalized","description":"Cost effectiveness assessment by number of patients hospitalized","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-scheduled Physician Visits","description":"Cost effectiveness assessment by number of patients with non-scheduled physician visits","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Genotypic Resistance Associated With Virologic Failure","description":"Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment-emergent AIDS-defining Illness","description":"Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":null},{"groupId":"OG001","value":"186","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment-emergent AIDS-defining Illness Leading to Death","description":"Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"373","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]}]},{"type":"SECONDARY","title":"Lipodystrophy","description":"Number of patients with AE lipodystrophy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"375","spread":null},{"groupId":"OG001","value":"192","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Lipid Abnormalities","description":"Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"367","spread":null},{"groupId":"OG001","value":"189","spread":null}]}]}]},{"type":"SECONDARY","title":"Glycaemic Abnormalities","description":"Number of patients with AE elevated serum glucose","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"376","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 96","description":"Treatment response is defined as a viral load (VL) \\<50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"122","spread":null},{"groupId":"OG002","value":"253","spread":null},{"groupId":"OG003","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"123","spread":null},{"groupId":"OG003","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response at Week 144","description":"Treatment response is defined as a viral load (VL) \\<50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"234","spread":null},{"groupId":"OG003","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"142","spread":null},{"groupId":"OG003","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Virological Rebound With VL >=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144","description":"The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Virological Rebound With VL >=400 Copies/mL After CVR at Week 24, 48, 96, 144","description":"The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Virologic Failure at Week 48, 96, 144","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"45","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"40","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Response (First Confirmed VL<50 Copies/mL)","description":"Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.00","spread":null},{"groupId":"OG001","value":"12.14","spread":null},{"groupId":"OG002","value":"12.00","spread":null},{"groupId":"OG003","value":"23.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Loss of Virologic Response (Rebound)","description":"Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143.86","spread":null},{"groupId":"OG001","value":"143.21","spread":null},{"groupId":"OG002","value":"143.71","spread":null},{"groupId":"OG003","value":"143.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure","description":"Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count \\< 50 copies/mL up to Visit 10 (week 48) or loss of virologic response","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143.86","spread":null},{"groupId":"OG001","value":"143.21","spread":null},{"groupId":"OG002","value":"143.71","spread":null},{"groupId":"OG003","value":"143.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144","description":"Calculations based on the MDRD algorithm.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.91","spread":"13.93"},{"groupId":"OG001","value":"-5.92","spread":"17.11"},{"groupId":"OG002","value":"-4.86","spread":"15.52"},{"groupId":"OG003","value":"-7.18","spread":"15.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.93","spread":"14.33"},{"groupId":"OG001","value":"-10.02","spread":"17.37"},{"groupId":"OG002","value":"-8.42","spread":"15.92"},{"groupId":"OG003","value":"-11.53","spread":"15.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.27","spread":"20.65"},{"groupId":"OG001","value":"-6.33","spread":"17.30"},{"groupId":"OG002","value":"-4.82","spread":"19.06"},{"groupId":"OG003","value":"-9.56","spread":"17.47"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With >= DAIDS Grade 2 Laboratory Abnormalities","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Reporting Rash of Any Severity","description":"Proportion of Patients reporting rash of any severity","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Reporting Hepatic Events of Any Severity","description":"Proportion of Patients reporting hepatic events of any severity","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity","description":"Proportion of Patients reporting CNS (central nervous system) side effects of any severity","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Change of Cholesterol Values From Baseline to Week 48, 96, 144","description":"Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.28","spread":"30.64"},{"groupId":"OG001","value":"29.54","spread":"27.33"},{"groupId":"OG002","value":"20.84","spread":"30.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.17","spread":"33.67"},{"groupId":"OG001","value":"36.87","spread":"30.60"},{"groupId":"OG002","value":"29.99","spread":"31.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.12","spread":"32.77"},{"groupId":"OG001","value":"30.66","spread":"33.24"},{"groupId":"OG002","value":"28.13","spread":"32.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.54","spread":"24.44"},{"groupId":"OG001","value":"17.70","spread":"22.16"},{"groupId":"OG002","value":"10.58","spread":"26.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.93","spread":"23.44"},{"groupId":"OG001","value":"21.66","spread":"25.14"},{"groupId":"OG002","value":"19.19","spread":"25.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.42","spread":"26.61"},{"groupId":"OG001","value":"17.95","spread":"26.04"},{"groupId":"OG002","value":"17.61","spread":"28.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.06","spread":"9.72"},{"groupId":"OG001","value":"11.59","spread":"10.95"},{"groupId":"OG002","value":"3.49","spread":"9.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.86","spread":"10.95"},{"groupId":"OG001","value":"13.33","spread":"12.00"},{"groupId":"OG002","value":"4.74","spread":"10.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.61","spread":"13.64"},{"groupId":"OG001","value":"10.47","spread":"15.35"},{"groupId":"OG002","value":"5.73","spread":"11.14"}]}]}]},{"type":"SECONDARY","title":"Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144","description":"Changes frombaseline apolipoprotein A1 \\& B","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.22"},{"groupId":"OG001","value":"0.23","spread":"0.24"},{"groupId":"OG002","value":"0.08","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.24"},{"groupId":"OG001","value":"0.23","spread":"0.25"},{"groupId":"OG002","value":"0.07","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.24"},{"groupId":"OG001","value":"0.14","spread":"0.26"},{"groupId":"OG002","value":"0.06","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.17"},{"groupId":"OG001","value":"0.03","spread":"0.16"},{"groupId":"OG002","value":"0.03","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.16"},{"groupId":"OG001","value":"-0.00","spread":"0.17"},{"groupId":"OG002","value":"0.03","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.16"},{"groupId":"OG001","value":"0.05","spread":"0.18"},{"groupId":"OG002","value":"0.03","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Change of hsCRP From Baseline to Week 48, 96, 144","description":"Change of hsCRP from baseline to week 48, 96, 144","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"12.53"},{"groupId":"OG001","value":"-0.67","spread":"12.71"},{"groupId":"OG002","value":"-0.70","spread":"8.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.54","spread":"11.21"},{"groupId":"OG001","value":"-0.79","spread":"21.32"},{"groupId":"OG002","value":"0.35","spread":"15.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"14.34"},{"groupId":"OG001","value":"-0.02","spread":"12.76"},{"groupId":"OG002","value":"0.04","spread":"8.20"}]}]}]},{"type":"SECONDARY","title":"Change of Total Triglycerides From Baseline to Week 48, 96, 144","description":"Change of total triglycerides from baseline to week 48, 96, 144","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"92.39"},{"groupId":"OG001","value":"1.67","spread":"99.31"},{"groupId":"OG002","value":"36.28","spread":"80.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.34","spread":"95.66"},{"groupId":"OG001","value":"5.35","spread":"84.92"},{"groupId":"OG002","value":"30.45","spread":"94.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.46","spread":"77.97"},{"groupId":"OG001","value":"6.11","spread":"80.82"},{"groupId":"OG002","value":"27.11","spread":"85.97"}]}]}]},{"type":"SECONDARY","title":"Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144","description":"Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.95"},{"groupId":"OG001","value":"-0.33","spread":"1.05"},{"groupId":"OG002","value":"0.20","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.93"},{"groupId":"OG001","value":"-0.25","spread":"1.03"},{"groupId":"OG002","value":"0.28","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.96"},{"groupId":"OG001","value":"-0.07","spread":"1.45"},{"groupId":"OG002","value":"0.17","spread":"1.05"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":188},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Rash","Bronchitis"]}}}